Log in Free sign up

Phio Pharmaceuticals (PHIO) News and press releases

News

From Benzinga Pro

Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells

Biotech, News, Penny Stocks, Health Care, General

12 Health Care Stocks Moving In Monday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity Of HER2-CAR-T Cells At ASGCT 2022

Biotech, News, Events, General

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

Phio Pharmaceuticals Q1 EPS $(0.19) Up From $(0.32) YoY

Phio Pharmaceuticals (NASDAQ:PHIO) reported quarterly losses of $(0.19) per share. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year.

Phio Pharmaceuticals Announces Upcoming Presentation Of PH-894 Data At ASGCT 25th Annual Meeting 2022

Biotech, News, Events, General

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,

Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma

Biotech, News, Penny Stocks, Health Care, FDA, General

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.

Phio Pharma Reports Commencement Of Its Phase 1b Trial Of PH-762 For Treatment Of Advanced Melanoma

Biotech, News, FDA, General

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,

22 Stocks Moving in Friday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and SNDBX reported a strategic partnership for gaming and e-Sports.

Phio Pharmaceuticals To Present At Tumor Immune Microenvironment Workshop Of The Society For Immunotherapy Of Cancer On Apr. 21

Biotech, News, Events, General

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation

Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has

12 Health Care Stocks Moving In Friday's Intraday Session

Intraday Update, Markets, Movers

Phio Pharmaceuticals Presents Positive Data On PH-894 Demonstrating Antitumor Efficacy In Model Of PD-1 Refractory Disease At AACR Annual Meeting 2022

News, FDA, Events

hio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

Phio Pharmaceuticals Granted U.S. Patent #11,279,934 Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

Options, Markets

View patent here

Phio Pharmaceuticals Announces Upcoming Presentation Of PH-894 Data At The AACR Annual Meeting 2022

News, FDA, Events

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Puma Biotechnology (NASDAQ:PBYI) shares moved upwards by 12.0% to $2.61 during Thursday's after-market session. The company's market cap stands at $106.7 million. As per the press release, Q4 earnings came out today.

Phio Pharmaceuticals Initiates In Vivo Studies Of INTASYL Based Antivirals Against SARS-CoV-2

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

Press releases

From Benzinga Pro

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Earnings, Press Releases

First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass., May 12, 2022

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

MARLBOROUGH, Mass., May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

MARLBOROUGH, Mass., May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022

Marlborough, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

MARLBOROUGH, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma

MARLBOROUGH, Mass., April 26, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Thinking about buying stock in Indonesia Energy, Phio Pharmaceuticals, Redbox Entertainment, DiDi Global, or Cleveland-Cliffs?

Opinion, Press Releases

NEW YORK, April 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, PHIO, RDBX, DIDI, and CLF.

Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer

MARLBOROUGH, Mass., April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Thinking about buying stock in Agile Therapeutics, Polarityte, Bed Bath & Beyond, Tellurian, or Phio Pharmaceuticals?

Opinion, Press Releases

NEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, PTE, BBBY, TELL, and PHIO.

Thinking about buying stock in Nio, Genocea Biosciences, Phio Pharmaceuticals, IQIYI, or Aterian?

Opinion, Press Releases

NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, GNCA, PHIO, IQ, and ATER.

Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism

Health Care, Markets, Press Releases

NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO's of: Nova Mentis Life Sciences

Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022

MARLBOROUGH, Mass., April 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update

Earnings, Press Releases

Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass., March 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022

MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering

Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

MARLBOROUGH, Mass., Feb. 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering